Search

You searched for "glans"

1113 results found

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

From nursery rhyme to science

1 May 2014 | | URO - Endourology & Stones, URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the BAUS Virtual Museum of the History of Urology which is part of the BAUS website (www.baus.org.uk). In the last two articles I...

Penile Mondor’s disease

1 January 2019 | | URO - Andrology
Mondor’s disease is a rare, self-limiting entity characterised by subcutaneous chord like bands throughout the body. These bands arise due to phlebitis of the subcutaneous vessels. Penile Mondor’s disease (PMD) is an isolated superficial thrombophlebitis of the superficial dorsal vein...

EBM Stats Calc: there’s a stat for that

1 November 2018 | | URO - Basic Science Research, URO - Technology
Quantifying the value of a specific test or intervention for a patient is no easy feat. Even when the value of a given test or intervention has been established, there may be additional case-specific factors to consider that are not...

BAUS Web App

6 November 2024 | | URO - Technology
The British Association of Urological Surgeons (BAUS) launched a new web app in June 2024 [1] at their annual meeting in Birmingham. This innovative platform is designed to enhance the user experience for members.Unlike traditional apps, the BAUS web app...

Metabolic screening and stone-prevention in urolithiasis patients

1 July 2017 | | URO - Endourology & Stones
The incidence and prevalence of kidney stones is increasing [1,2]. Significant recurrence rates are noted with 14% of patients experiencing a further episode at one year, 35% at five years, and 52% at 10 years [3]. Over 10% of stone...

Men with a susceptibility to prostate cancer: implications of family history in PCa risk-prediction

3 September 2021 | | URO - Urologic Oncology
Incorporation of family history (FH) status into prostate cancer (PCa) risk stratification has the potential to underpin many aspects of PCa care. This group of men presents a unique challenge in early cancer detection, particularly given that most men without...

An old resectoscope in a wooden case

1 January 2017 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would write about a particular artefact...

What did the Romans ever do for us?

1 May 2016 | | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Previously in this column, I told you about the Saxons and how they...

Post radical nephrectomy presenting with skull metastasis

10 April 2024 | | URO - Urologic Oncology
We present the case of an 83-year-old female who underwent right radical nephrectomy for renal cell carcinoma (RCC). Despite negative surgical margins, the patient presented with a skull metastasis six years post radical nephrectomy. This case highlights the importance of...

Transplant urology at Guy’s Hospital: making the most of a year out before specialty training

7 January 2020 | | URO - Functional / Reconstructive Urology
It was gutting to miss out on urology at national selection on my first attempt. The ST3 application has become increasingly competitive and this means more appointable trainees find themselves looking to plan B. The options available can be daunting...

Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators

11 July 2023 | | URO - Functional / Reconstructive Urology
Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...